The abstract is read at the publisher; the summary is JClub's.
CD25-biased IL2Mut24 expands Tregs in mice but paradoxically worsens cutaneous inflammation, with ILC2-driven, CD25-dependent innate activation linked to skin toxicity.
- Why it matters: IL-2 muteins aim to boost Tregs for autoimmune therapy, yet injection site reactions and inflammation limit safety and remain mechanistically unclear.
- What they did: In immunodeficient mice, antibody blockade and adoptive transfer were used to identify ILC2s as drivers of IL-2-induced skin inflammation; cynomolgus monkeys then tested CD25-biased efavaleukin alfa versus aldesleukin.
- The result: Receptor clamps that restrict IL2Mut24 access to CD25 preserved Treg selectivity, suppressed injection site reactions, and outperformed IL2Mut24 in experimental autoimmune encephalomyelitis by restraining Th17 responses.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.